Lightstone Ventures

Dive into the investment focus areas of Lightstone Ventures with McDermott + Bull's Ken Dropiewski and Mike Carusi. Discover where Lightstone is channeling its resources. Check out their full conversation here: https://lnkd.in/gvSeG3M3 #InvestorInsights #LifeSciences #MedTech #Investing #Finance #VentureCapital

🎥 View our latest #ClavystBioConversations for a masterclass in #MedTech venture-building! 🚀 Moderated by ClavystBio’s Yingmin Wang, Lightstone Ventures' Mike Carusi and Allay Therapeutics’ Koon Kiat Teu dive into Allay's exciting growth journey —sharing pivotal lessons, challenges, and insights for entrepreneurs and innovators. Watch the full conversation here: https://lnkd.in/gsd8XTvU #Medtech #Innovation #Entrepreneurship ClavystBio Lightstone Ventures Allay Therapeutics National Health Innovation Centre (NHIC)

📢 Exciting News: Atsena Therapeutics Announces Exclusive Strategic Collaboration with Nippon Shinyaku for ATSN-101 in the U.S. and Japan! 🎉   We’re thrilled to share that we have entered into an exclusive license agreement with Nippon Shinyaku to commercialize and develop our first-in-class, investigational ocular #GeneTherapy ATSN-101 to treat Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). This partnership marks a significant step forward in our mission to bring life-changing therapies to those affected by #InheritedRetinalDiseases.   Together, we aim to push the boundaries of what’s possible in ocular gene therapy, advancing multiple clinical programs and our novel technologies. We anticipate this will be the first of many ocular gene therapy treatments from our clinical portfolio to come! 👁️✨   Read the full press release here: https://lnkd.in/ejwUjFAG Visual description: The image features a portrait of Patrick Ritschel, Chief Executive Officer of Atsena Therapeutics, on the left side. On the right side, against a gradient background that transitions from purple at the top to blue at the bottom, with a dotted texture, there is white text displaying a quote from Mr. Ritschel:    “This collaboration creates a path to accelerate the development of ATSN-101 and validates Atsena’s pioneering technology and development capabilities. We look forward to working with Nippon Shinyaku as we advance ATSN-101 into a pivotal trial and potential approval to provide an innovative solution to patients and families affected by LCA1 around the world.”    The Atsena Therapeutics logo is In the bottom right corner.

Join Edwards Lifesciences’ Perry Bridger, Lightstone Ventures’ Mike Carusi, and Medical Device Innovation Consortium (MDIC)’s Harry Kotlarz at Innovation Summit San Diego 2024 in the panel session “Cracking the Black Hole of Private Payer Reimbursement.” 🎙️ Stephen Levin, Editor-in-Chief of Market Pathways, will be moderating the discussion featuring these esteemed panelists on Wednesday, November 20 from 10:35-11:15AM: Perry Bridger is Senior Advisor to Edwards Lifesciences where he provides strategic commercialization, market access, and public affairs guidance to the company’s executive leadership team. He established the company’s integrated global market access functions in 2011. Mike Carusi is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Menlo Park, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Allay Therapeutics, Altura Medical (acquired by Lombard), Ardian (acquired by Medtronic), Cala Health, EndoGastric Solutions, Gynesonics, MediSix Therapeutics, MicroVention (acquired by Terumo), Nuvaira, Plexxikon (acquired by Daiichi Sankyo), PowerVision (acquired by Alcon), Second Genome, Shoulder Innovations, Tallac Therapeutics, and Willow. Harry Kotlarz brings more than two decades of leading health economics and market access functions to his role. His blend of industry experience, multiple stakeholder engagement, and evidence-based solutions has contributed to coverage and access for innovative technologies helping more patients.   He has been responsible for the evidence required for value-based healthcare, reimbursement, and health policy-related issues including quality, new payment models, comparative effectiveness, and cost-effectiveness outcomes. Welcome to #InnovationSanDiego, Perry, Mike, and Harry! Climb the Summit to #MedTech Innovation November 19-21, 2024 at The US Grant Hotel in San Diego, California to easily connect and network with the industry's top key players without the typical conference hurdles. Register today: https://bit.ly/4gBjKW6

We are excited to announce the completion of enrollment in the "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. The FASTR trial aims to compare the effectiveness of decongestive therapy administered by the Reprieve System with Optimal Diuretic Therapy in patients diagnosed with acute decompensated heart failure. Completing enrollment in the FASTR trial marks a significant milestone for Reprieve as we advance our mission to improve the lives of patients living with heart failure. Go here to learn more: https://lnkd.in/ehrB84_U

Tagworks is excited to announce a management update. Ken Mills has been appointed our new CEO, and our founding CEO Marc Robillard will continue in the role of CSO and Board member. We are proud of our leadership team and look forward to working together to advance our first clinical candidates in order to bring novel cancer treatments to patients with solid tumors. Read the press release here: https://lnkd.in/eE4cZhzC

We are thrilled to announce that the FDA has granted Orphan Drug Designation to Atsena Therapeutics for our best-in-class #ocular #GeneTherapy ATSN-201, targeting X-linked retinoschisis (XLRS), a rare #InheritedRetinalDisease with no approved treatments that affects approximately 30,000 males in the U.S. and EU.   This important milestone comes shortly after ATSN-201 received Rare Pediatric Disease designation from the FDA and recognizes the significant unmet need for treatment options for those affected by XLRS. It also underscores our commitment to pioneering innovative gene therapies that improve patients’ lives. https://lnkd.in/efaJfm_R   Visual description:   The image features a photograph of Patrick Ritschel, Chief Executive Officer of Atsena Therapeutics. To the right of his photo, there is a quote attributed to him:   "We are honored to receive the FDA’s Orphan Drug Designation for ATSN-201, which was also recently granted Rare Pediatric Disease designation. These designations mark a significant inflection point for the potential of this ocular gene therapy. We are confident these designations will expedite our path forward."   At the bottom of the quote, his name and title appear. In the bottom right corner is the Atsena Therapeutics logo in white, along with the company name written in capital letters. A gradient background transitions from purple at the top to blue at the bottom, featuring a pattern of small dots. There are curved lines in blue, orange, and purple encircling the photograph of Patrick Ritschel.

We are excited to share that The Lancet published 12-month safety and efficacy data from our Phase I/II clinical trial evaluating ATSN-101 the first, investigational #GeneTherapy therapy to treat the #InheritedRetinalDisease #LeberCongenitalAmaurosis caused by biallelic mutations in GUCY2D (LCA1).   ATSN-101 demonstrated durable, clinically significant improvements in vision and was well-tolerated 12 months post-treatment. We are encouraged by these promising results, which support further evaluation in a Phase III trial. ATSN-101 has the potential to become the first-ever #GeneTherapy for LCA1, marking a significant advancement in reversing blindness that begins in childhood.   Read the full article published online in The Lancet. https://lnkd.in/eCsf8Khq   Image description: Text reads: Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/ll Clinical Trial of ATSN-101 in LCA1 Published in The Lancet. The Atsena Therapeutics logo is in the bottom right corner over a white bar stretching across the bottom.

We’re thrilled to share that #65LAB has awarded its inaugural grant to Associate Professor Lena Ho from Duke-NUS Medical School to develop first-in-class therapeutics for chronic inflammation.   Selected through a competitive process, Assoc Prof Ho worked closely with 65LAB Expert-in-Residence Stephen Hess to develop a work plan that meets industry benchmarks, and positions her project for commercialization.   Her project will receive a total of US $1.85 million in funding, with US$1.5 million from 65LAB and an additional US$350,000 from Duke NUS’ newly established incubator LIVE Ventures.   Learn more about this milestone here: https://lnkd.in/ghyRNnTF   Duke-NUS Medical School ClavystBio Leaps by Bayer Lightstone Ventures Polaris Partners Evotec Evotec BRIDGEs

📣 Volta Medical is thrilled to announce a joint development agreement with GE HealthCare to enhance arrhythmia procedures! Through this collaboration, we aim to integrate our #AI solution Volta AF-Xplorer™ with GE HealthCare's digital platform Prucka™ 3, and CardioLab™ EP recording system, and streamline workflows for electrophysiologists during catheter ablation procedures to treat #AFib.⚡ 🔗 Click the link to read the full press release and learn more about this initiative : https://lnkd.in/eW5VPHuF #Collaboration #Electrophysiology #AI #AtrialFibrillation #EPeeps #Innovation